Oncology Certified Nurse Practice Test 2026 – Complete Exam Prep

Elevated levels of ADH (antidiuretic hormone) and ACTH (adrenocorticotropic hormone) in patients with lung cancer, especially those with small cell lung cancer, are often due to the tumor's ability to produce ectopic hormones or hormone-like substances. Small cell lung cancer has a propensity to secrete these hormones as a paraneoplastic syndrome, where the tumor's growth leads to hormone imbalances in the body that are unrelated to normal physiological processes.

In this context, the tumor cells may express proteins that resemble ADH and ACTH, triggering the body's hormonal responses as if these are being released from the normal endocrine glands. This can lead to conditions such as syndrome of inappropriate antidiuretic hormone secretion (SIADH) and ectopic Cushing's syndrome arising from ACTH secretion, both of which can cause an array of clinical symptoms and complications.

This understanding is crucial in managing lung cancer patients presenting with these hormonal elevations, as it highlights the importance of identifying the underlying cancer-related processes rather than attributing the changes solely to the cancer itself or its treatment. It underscores the need for comprehensive care that addresses the complex interactions between cancer and the body’s endocrine system.